Literature DB >> 17410928

[Dialectical behavior therapy for adolescents with anorexia and bulimia nervosa (DBT-AN/ BN)--a pilot study].

Harriet Salbach1, Nora Klinkowski, Ernst Pfeiffer, Ulrike Lehmkuhl, Alexander Korte.   

Abstract

Dialectical behavior therapy (DBT) was originally developed by Linehan (1993a, b) and modified by Miller et al. (1997) for suicidal adolescents with borderline personality features. Meanwhile, this therapy has also successfully applied in other adult clinical groups. The prior aim of the study is to evaluate the effectiveness of DBT for inpatient adolescents with anorexia and bulimia nervosa. In this pilot study (n=31) the efficacy of this treatment will be evaluated in a pre-post comparison. Different instruments will be used (SIAB, EDI-2, SCL-90-R, FBB). The first results are promising and we must hope that this new approach will improve the future treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17410928     DOI: 10.13109/prkk.2007.56.2.91

Source DB:  PubMed          Journal:  Prax Kinderpsychol Kinderpsychiatr        ISSN: 0032-7034


  3 in total

1.  Outcome from a randomized controlled trial of group therapy for binge eating disorder: comparing dialectical behavior therapy adapted for binge eating to an active comparison group therapy.

Authors:  Debra L Safer; Athena Hagler Robinson; Booil Jo
Journal:  Behav Ther       Date:  2010-01-25

2.  [Guideline-adherent inpatient psychiatric psychotherapeutic treatment of borderline personality disorder : Normative definition of personnel requirements].

Authors:  M Bohus; C Schmahl; S C Herpertz; K Lieb; M Berger; S Roepke; A Heinz; J Gallinat; L Lyssenko
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

3.  Subjective evaluation of outpatient treatment for adolescent patients with anorexia nervosa.

Authors:  Charlotte Jaite; Antje Pfeiffer; Ernst Pfeiffer; Claudia Thurn; Tobias Bierbaum; Sibylle Maria Winter; Ulrike Lehmkuhl; Harriet Salbach
Journal:  Eat Weight Disord       Date:  2018-11-29       Impact factor: 4.652

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.